Bristol-Myers Squibb Co. and AstraZeneca Plc’s new diabetes pill may cause breast and bladder cancer, according to U.S. regulators weighing whether to clear sales of the medicine, reports Bloomberg. While Food and Drug Administration staff said the drug is effective, they focused on safety concerns in a review of dapagliflozin released ahead of a July 19 FDA advisory panel meeting in Silver Spring, Maryland. New York-based Bristol-Myers and AstraZeneca of London have said they expect a final decision on approval by Oct. 28. The companies said in June that more bladder and breast cancers were seen in patients taking the new medicine instead of a placebo in studies. Regulators have increased scrutiny of diabetes pills since GlaxoSmithKline’s top-selling Avandia was tied to heart attacks in 2007 and was ultimately forced off the market in Europe and severely restricted in the U.S. Nine cases of bladder cancer occurred in male patients who took dapagliflozin, compared with one case among people treated with a placebo. Breast cancer occurred in nine patients who took dapagliflozin, and one patient in the control group. FDA staff also said the drug was less effective in patients with impaired kidney function.